A proposed oral treatment for Type 1 diabetes in adults has been rejected in the U.S.
The rejection of what would have been the first oral treatment for Type 1 diabetes in the U.S. is a big setback for Lexicon Pharmaceuticals Inc.
, a small company based in a Houston suburb that currently has one product on the market and losses of nearly $1.5 billion as of Dec. 31. Lexicon is developing the treatment, which is called Zynquista, with French pharmaceutical giant Sanofi.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetesThe U.S. Food and Drug Administration declined to approve a drug developed by Sa...
Lire la suite »
FDA approves the first drug designed to treat postpartum depressionThe FDA approved the first drug specifically for postpartum depression, a debilitating condition that affects about 400,000 women a year in the United States.
Lire la suite »
FDA says cybersecurity vulnerabilities found in some Medtronic devicesThe U.S. Food and Drug Administration (FDA) on Thursday said cybersecurity vulne...
Lire la suite »
Indonesian airline Garuda is canceling its $6 billion order for 49 Boeing 737 Max jetsBoeing 737 Max planes have been grounded by authorities after two recent fatal crashes.
Lire la suite »
FDA approves first treatment for postpartum depressionThe FDA has approved a new medication called Zulresso, a completely new class of drug designed specifically to treat postpartum depression. It’s a one-time infusion given in a hospital over two and a half days.
Lire la suite »
FDA issues warning to two breast implant makers over safety concernsLess than a week before a major hearing on breast implant safety, the FDA issued two warning letters to implant manufacturers, citing their failure to do proper safety studies.
Lire la suite »
Sage Therapeutics’ Drug for Postpartum Depression Gets FDA NodU.S. health regulators on Tuesday approved Sage Therapeutics Inc.’s Zulresso, the first medication specifically intended for women with postpartum depression.
Lire la suite »